Biodexa Pharmaceuticals Statistics
Total Valuation
BDRX has a market cap or net worth of $4.28 million. The enterprise value is $3.10 million.
Important Dates
The next estimated earnings date is Monday, September 29, 2025, before market open.
| Earnings Date | Sep 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BDRX has 619,523 shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 619,523 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +101.93% |
| Owned by Insiders (%) | 0.45% |
| Owned by Institutions (%) | 6.50% |
| Float | 608,275 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.04 |
| P/TBV Ratio | 1.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.75, with a Debt / Equity ratio of 0.09.
| Current Ratio | 1.75 |
| Quick Ratio | 0.47 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -55.75 |
Financial Efficiency
Return on equity (ROE) is -88.14% and return on invested capital (ROIC) is -81.03%.
| Return on Equity (ROE) | -88.14% |
| Return on Assets (ROA) | -45.41% |
| Return on Invested Capital (ROIC) | -81.03% |
| Return on Capital Employed (ROCE) | -94.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$551,714 |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -312,981 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.26% in the last 52 weeks. The beta is 0.99, so BDRX's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | -95.26% |
| 50-Day Moving Average | 8.95 |
| 200-Day Moving Average | 27.32 |
| Relative Strength Index (RSI) | 34.64 |
| Average Volume (20 Days) | 36,767 |
Short Selling Information
| Short Interest | 17,965 |
| Short Previous Month | 364,674 |
| Short % of Shares Out | 2.90% |
| Short % of Float | 2.95% |
| Short Ratio (days to cover) | 0.14 |
Income Statement
| Revenue | n/a |
| Gross Profit | -6.81M |
| Operating Income | -11.52M |
| Pretax Income | -9.56M |
| Net Income | -7.17M |
| EBITDA | -11.37M |
| EBIT | -11.52M |
| Earnings Per Share (EPS) | -$144.81 |
Full Income StatementBalance Sheet
The company has $2.09 million in cash and $910,149 in debt, giving a net cash position of $1.18 million or $1.90 per share.
| Cash & Cash Equivalents | 2.09M |
| Total Debt | 910,149 |
| Net Cash | 1.18M |
| Net Cash Per Share | $1.90 |
| Equity (Book Value) | 10.42M |
| Book Value Per Share | 155.83 |
| Working Capital | 4.73M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.35 million and capital expenditures -$11,267, giving a free cash flow of -$16.66 million.
| Operating Cash Flow | -15.35M |
| Capital Expenditures | -11,267 |
| Free Cash Flow | -16.66M |
| FCF Per Share | -$26.90 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |